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Despite the success of alginate scaffolds and mesenchymal stem cells (MSCs) therapy in cardiac failure treat-
ment, the impact of the physicochemical environment provided by alginate matrices on cell behavior has never 
been investigated. The purpose of this work was double: to determine the alginate composition influence on 
(1) encapsulated rat MSC viability, paracrine activity, and phenotype in vitro and (2) cardiac implantability and 
in vivo biocompatibility of patch shape scaffolds. Two alginates, differing in composition and thus presenting 
different mechanical properties when hydrogels, were characterized. In both cases, encapsulated MSC viability 
was maintained at around 75%, and their secretion characteristics were retained 28 days postencapsulation. In 
vivo study revealed a high cardiac compatibility of the tested alginates: cardiac parameters were maintained, 
and rats did not present any sign of infection. Moreover, explanted hydrogels appeared surrounded by a vascu-
larized tissue. However, scaffold implantability was highly dependent on alginate composition. G-type alginate 
patches, presenting higher elastic and Young moduli than M-type alginate patches, showed a better implanta-
tion easiness and were the only ones that maintained their shape and morphology in vivo. As a consequence 
of alginate chemical composition and resulting hydrogel structuration, G-type alginate hydrogels appear to be 
more adapted for cardiac implantation.
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them during surgical intervention, (2) concentrates them 
on the ischemic area, (3) improves grafted MSC viability, 
(4) preserves their paracrine activities and their undiffer-
entiated state, and (5) provides a physical support whose 
mechanical properties are in accordance with a cardiac 
implantation and in vivo environment. 
Alginate hydrogels present an increasing interest 
to elaborate medical devices in cardiac therapy field. 
Different studies distinguished two main strategies using 
alginate-based biomaterials after myocardial infarction. 
The first one concerns injectable alginate implants as 
an acellular strategy (21,31,33,64,65). In this case, algi-
nate is directly injected either into the myocardium or 
intra coronary to supply a physical support for improved 
healing and repair. The second strategy uses alginate 
hydrogels as cardiac patches for integration of newly 
formed vascularized tissue into the host myocardium 
(2,15,32). These examples validate the feasibility of using 
alginate as biomaterial in the treatment of heart diseases, 
INTRODUCTION
The potential of mesenchymal stem cells (MSCs) for 
the treatment of myocardial infarction is now established. 
Their beneficial effects appear to be mainly attributed 
to their paracrine activities providing a regenerative 
microenvironment at the ischemic area (8,9,55,63). Direct 
injection in the necrotic zone of bone marrow (BM)-
derived MSCs is already tested as a therapeutic strategy 
subsequently to myocardial infarction and reperfusion in 
clinical trials (62). Unfortunately, benefits of such regen-
erative therapy are limited by early cell death (around 
85%) in the first 3 days after graft (34,38,48,54,57,61). 
These limitations depend on different mechanisms such 
as hypoxia, inflammation, or mechanical stress occurring 
during surgical implantation. Therefore, strategies con-
cerning preservation of cell viability and functionality 
after implantation are becoming a priority in cardiac cell 
therapy (7,41,52,53). A promising strategy is to associ-
ate MSCs with a biocompatible material that (1) protects 
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but little is known about the influence of alginate compo-
sition on biomaterial final properties in this domain. 
Alginates are very hopeful for health applications 
due to their structural similarities with extracellular 
matrix, their properties to gelify under soft conditions 
and their low toxicity after purification. Alginates are 
a family of naturally derived polymers extracted from 
sea brown algae. Alginates are unbranched binary copo-
lymers consisting of 1,4-linked β-d-mannuronic (M) 
and α-l-guluronic (G) residues organized in regions of 
sequential G units (G-blocks), regions of sequential M 
units (M-blocks), and regions of atactically organized G 
and M units. Sol–gel transition properties of alginates 
are based on the formation of a stiff “egg-box” struc-
ture due to the selective binding of divalent cations to 
G-blocks of two adjacent polymeric chains (18). As a 
consequence, the structure of alginate network is closely 
related to their monomeric and diadic organization. By 
varying their M/G proportions and distributions, it is 
possible to modulate the viscoelastic properties of the 
resulting crosslinked hydrogel. 
In this context, it seems reasonable to hypothesize that the 
choice of the alginate composition may have a determin-
ing impact on the device characteristics and performance. 
Recent studies demonstrated the importance of cellular 
environment on matrix entrapped cells (16) and more 
particularly the effects of mechanical properties (5) and 
chemical composition (10,23,47,50,51,59) of alginates 
on stem cell behavior in pancreatic, neural, and cartilage 
tissue engineering fields. These observations underline 
the relevance of this parameter to design the best suitable 
device for the targeted application. Concerning cardiac 
applications, a complete bibliographic study reveals a 
lack of argumentation in this domain, as already reported 
injectable alginates and alginate patches appeared to be 
either G-type (2,15,21,31,33) or M-type (64,65), or even 
were sometimes not specified (1). As far as we know, the 
impact of alginate composition and resulting mechanical 
properties on MSC behavior has never been studied so far. 
With this scope, we firstly characterized two ultrapur algi-
nate samples with similar molecular weight and different 
chemical compositions. Secondly, we compared the influ-
ence of alginate MSCs entrapment on cell viability and 
functionality in vitro. Finally, alginate composition influ-
ence was evaluated in vivo: calcium alginate hydrogels 
implantability and biocompatibility were evaluated after 
cardiac implantation in rats.
MATERIALS AND METHODS
MVG (G-type) and MVM (M-type) ultrapur grade 
sodium alginates were used (Provona up MVG and 
Provona up MVM, Novamatrix, Norway). Medium molec-
ular weight alginates were chosen to improve mechanical 
properties of the materials and to limit their in vivo deg-
radation (30).
Alginate Hydrogels Elaboration
Alginate concentration (1.2%, w/w) was chosen to opti-
mize encapsulation process. Hydrogels were prepared 
under aseptic conditions (all solutions were sterile fil-
tered and all equipment were autoclaved).
Alginate Dispersion. Solutions of 1.2% (w/w) MVG and 
MVM ultrapur alginate were prepared in iso- osmotic HEPES 
buffer (150 mM NaCl, 12.5 mM HEPES, pH 7.4) during 
30 min at 1800–2000 rpm (Heidolph RZR-2041, Germany).
Hydrogels Gelification
In Vitro Study. MSCs were encapsulated in alginate 
microspheres, which permitted to study MSC behavior 
in alginate-confined environment. Microencapsulations 
were performed upon generation of monodisperse droplets 
of sodium alginate solution, containing MSCs (2.5 mil-
lion of cells/ml of alginate solution) or not, by an encap-
sulator (IE50R, Inotech, Switzerland), equipped with a 
vibrating nozzle (300 µm, 850 Hz). Then ionotropic gela-
tion was performed in an iso-osmotic buffer containing 
calcium ions (CaCl2, 0.1 M) during 20 min. Constructs, 
containing approximately 2,300 cells per microsphere, 
were cultured in six-well plates in supplemented culture 
medium (α-MEM, 10% FBS, 1% penicillin/streptomycin, 
Gibco, France).
When necessary, cells were released from micro-
spheres by incubation in 55 mM sodium citrate for 20 min 
to liquefy alginate. Cell suspension was then centrifuged 
(400 rpm, 5 min).
In Vivo Study. Alginate patches were elaborated to 
allow a very close contact between alginate-based mate-
rials and heart. Sodium alginate solutions were placed in 
48-well plates. Then ionotropic gelation was performed 
in an iso-osmotic buffer containing calcium ions (CaCl2, 
0.1 M) for 20 min.
Alginate hydrogels were then washed three times 
(10 min in HEPES buffer) prior to in vitro cultivation or 
in vivo implantation.
1H NMR Spectroscopy
Protocols used are derived from the method described 
by Grasdalen et al. (19). The 1H NMR spectra of alginate 
in solution were recorded on a Avance DMX 500 MHz 
(Bruker Biospin Gmbh, Germany) operating at 500 MHz 
for 1H using a 5-mm broadband inverse probe head (BBI 
500 MHz). Prior to analysis, the average molecular 
weight of the alginate was reduced by a mild partial acid 
hydrolysis performed in two steps. Alginate (0.5 g) moist-
ened with 5 ml ethanol (96%) was dissolved in 50 ml HCl 
(pH 1.5). The pH was adjusted to 5.0 by addition of NaOH 
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and hydrolyzed at 100°C under reflux for 10 min. After 
cooling to room temperature, the pH was adjusted to 3.0 by 
addition of HCl and heated at 100°C under reflux for 
20 min. After cooling, the solution was neutralized (pH 7) 
by addition of NaOH and precipitated in ethanol (96%). 
The precipitate was left for drying overnight at 70°C. The 
hydrolyzed alginate was dissolved in D2O (1.0%, w/v) 
and neutralized (pH 7), and 550 µl of the solution was fil-
tered through a Whatman 13-mm syringe filter (pore size, 
0.45 mm) into a 5-mm NMR tube. The spectra were 
recorded with a 90° pulse angle and a sweep width of 
5,482 Hz. The acquisition time and recycle delay were both 
2 s. Thirty-two scans were acquired, and the spectra were 
recorded with the same receiver gain. During acquisition, 
the sample temperature was 90°C. 3-(Trimethylsilyl)pro-
pionic acid-d4 sodium salt (TSP-d4) was used as chemical 
shift reference compound (d = 0.0 ppm). The raw data were 
apodized by 1.0 Hz of exponential line broadening prior 
to Fourier transformation. No zero filling was applied.
Rheological Characterization
Rheological measurements were carried out using a 
stress-controlled rheometer (Rheostress RS75, HAAKE, 
Germany) with a parallel-plate geometry. Test samples 
were made to match the diameter of the parallel plate 
(20 mm). Gels were gently pressed with tissue paper 
to remove surface water before lowering the top plate. 
Stress sweeps at a constant frequency of 1 Hz were first 
performed to obtain the linear viscoelastic region for 
collecting subsequent data. Frequency sweeps were per-
formed in the linear viscoelastic regime to determine the 
elastic (G′) and viscous (G″) moduli values.
Texturometry
Young’s moduli and mechanical behavior of micro-
spheres were studied by three successive uniaxial 
compression assays (TA-XT2 Texture Analyzer, Stable 
Micro systems, UK). Briefly, mechanical resistance was 
determined as the main force required to generate a 50% 
compression of a sample of microparticles. The apparatus 
consisted of a mobile probe (314.16 mm2) moving verti-
cally up and down at constant and predefined velocity 
(0.5 mm/s). The force exerted by the probe on the micro-
spheres was recorded as a function of the displacement, 
leading to a force versus strain curve. The results were 
expressed as the average maximal mechanical stress in 
kPa observed at 50% of strain from at least three indepen-
dent observations.
Laser Diffraction Granulometry
Particles size distribution was assessed by laser dif-
fraction granulometer (LS100, Coulter, US) on G-type 
and M-type alginate microparticles in iso-osmotic HEPES 
buffer. Sauter diameter d(3,2) and polydispersity index 
were used to follow microspheres swelling, as an evalua-
tion of microspheres stability over time.
Isolation and Culture of Rat MSCs
MSCs were obtained from BM of Lewis male rats 
(Harlan, France) weighing 180–200 g. Anesthesia was 
performed by intraperitoneal injection of pentobarbital 
(0.1 ml/100 g). BM was flushed from rat’s femur with 
minimal essential medium (Gibco, France) supplemented 
with 10% fetal bovine serum (FBS) and 1% penicillin/ 
streptomycin (Invitrogen, France) and centrifuged (400 ×  g, 
5 min). Then cells were plated in culture flasks (100,000 
cells/cm2). After 3 days, nonadherent cells were removed 
by changing medium, and MSCs were recovered by 
their capacity to adhere highly to plastic culture dishes. 
MSCs were then routinely cultured and were used for the 
experiments. Most adherent cells expressed MSC mark-
ers CD90, CD29, CD106 and were negatives for CD34 
(hematopoietic marker), CD45 (B cells marker), and 
CD31 (vascular cells marker). They were able to differ-
entiate into cells from mesodermal lineage: osteoblasts, 
chondrocytes, and adipocytes. MSCs were used between 
the third and the sixth passage. 
Quantification of Cell Viability
A live/dead assay was performed with viability/cyto-
toxicity kit (FluoProbes®, Interchim, France). Briefly, 
microspheres were washed two times with α-MEM/
physiological serum (1:1) and immersed (30 min, 37°C) 
in presence of 2 µM ethidium homodimer-3 (necrotic 
marker measuring nucleus membrane integrity) and 
1 µM calcein AM (viability marker measuring intracel-
lular esterase activity) to stain dead cells in red and live 
cells in green. After washing with α-MEM, microspheres 
were observed by confocal microscopy (Zeiss LSM-FCS, 
Germany). Positive control for 100% cell death was 
obtained by treating microspheres containing encapsu-
lated MSCs with 70% ethanol for 10 min prior to fluores-
cent live/dead staining.
Two parameters were measured. First, cell viability, 
V, was calculated as the percentage of viable entrapped 
cells. V = NL/(NL + ND) with NL = Total green pixel num-
ber/number of green pixel per live cell and ND = Total red 
pixel number/number of red pixel per dead cell. The sec-
ond parameter was total cell density, D, expressed as the 
number of live and dead cells counted by microsphere 
area. D = (NL + ND)/Amicrosphere with Amicrosphere = area of the 
microsphere on which measurement was done.
Reverse Transcription-Polymerase Chain Reaction
Total RNA was isolated from 1 million of MSCs using 
RNeasy® Kit (Qiagen, France) according to the manu-
facturer’s protocol. RNA (8 ng) was reverse transcripted 
to cDNA using the SuperScript II reverse transcriptase 
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(Invitrogen, USA). The real-time RT-PCR was performed 
using SYBR Green PCR Master Mix (ABI Prism 7000 
HT Sequence Detection System, Applied Biosystems, 
USA). Amplification reactions (25 µl were carried out 
in triplicate with 5 µl of 1:10 diluted template cDNA) 
and the following primers (Eurogentec, Belgium) were 
used for the detection of vascular endothelial growth 
factor (VEGFα), hepatocyte growth factor (HGF), 
insulin-like growth factor (IGF1), epidermal growth 
factor (EGF), fibroblast growth factor (FGF2), and 
granulocyte colony-stimulating factor (G-CSF). Each 
assay was normalized by amplifying the housekeep-
ing cDNA glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and ribosomal protein L31 (RPL31) from the 
same cDNA sample and fold to nonencapsulated third 
passage MSCs.
VEGFα: 5′CAAAAACGAAAGCGCAAGAAA3′/
 5′GTCTGCGGATCTTGGACAAAC3′, 
HGF: AACAAGGTCTGGACTCACATG3′/
  5′CGTCTGGCTCCCAGAAGATATG3′, 
IGF1: 5′GACGGGCATTGTGGATGAGT3′/
  5′GGATGGAACGAGCTGACTTTG3′, 
EGF: 5′CTCACCCTCTCTCCTTGGAAAA3′/
 5′GGCGGGCATCCTGTGTT3′, 
FGF2: 5′GTGTGTGCGAACCGGTACCT3′/
  5′TATTGGACTCCAGGCGTTCAA3′, 
G-CSF:  5′TGTGGTGGTACCCAAGAAATCAC3′/
 5′CCTGGGCCCCTGAGACA3′,
GAPDH:    5′AGGTCGGTGTGAACGGATTTG3′/
 5′TGTAGACCATGTAGTTGAGGTCA3′,
RPL31: 5′CCATGGAGTGGGCTTCAAGA3′/
 5′TCTATGCGCACATCTGGAGTTC3′.
Western Blot
Proteins were extracted from MSCs using RIPA buf-
fer. Analyses were performed with samples normal-
ized for protein concentration. Membranes were probed 
with rabbit anti-FGF2 antibodies (1:500, Santa Cruz 
Biotechnology, USA). Following several washes in TBS-
Tween (0.2%), membranes were incubated with horse 
radish peroxidase (HRP)-conjugated anti-rabbit second-
ary antibody (1:10,000, Santa Cruz Biotechnology, USA). 
Protein expression was normalized by GAPDH expres-
sion (1:1,000, Santa Cruz Biotechnology).
Differentiation Assays
Protocols used are derived from the methods of 
Neuhuber et al. (39). 
Adipogenesis. MSCs were seeded into six-well plates 
at 20,000 cells/cm2 and cultured until confluency. Cultures 
were placed in adipogenic induction medium (Dulbecco’s 
modified Eagle’s medium with 4.5 mg/ml glucose, 10% 
fetal bovine serum, 5% rabbit serum and antibiotics, with 
0.5 mM isobutylmethylxanthine, 1 mM dexamethasone, 
10 mg/ml insulin, and 1 mM indomethacin) for 3 days 
and subsequently moved to adipogenic maintenance 
medium (Dulbecco’s modified Eagle’s medium with 
4.5 g/ml glucose, 10% fetal bovine serum, 5% rabbit 
serum, antibio tics, and 10 mg/ml insulin) for 1 day. After 
three cycles, cells remained in maintenance medium for 
7 days prior to fixation with 4% paraformaldehyde. 
Cells were stained with Oil Red O to visualize neutral 
lipid accumulation.
Chondrogenesis. Five hundred thousand MSCs were 
pelleted in high-glucose Dulbecco’s modified Eagle’s 
medium with 1% fetal bovine serum, antibiotics, 50 mg/ml 
ascorbate 2-phosphate, 40 mg/ml proline, 2 mM pyruvate, 
insulin/transferrin/selenium/linoleic acid (ITSþ), 100 nM 
dexamethasone, 10 ng/ml transforming growth factor-b3, 
and 200 ng/ml recombinant bone morphogenic protein-2. 
Medium was changed three times per week. On day 21, 
pellets were fixed in 4% paraformaldehyde, embedded 
in paraffin, and sectioned (6 µm). Sections were stained 
with Alcian blue to reveal mucopolysaccharides and 
glycosaminoglycans. 
Osteogenesis. MSCs were seeded in six-well dishes at 
3,000 cells/cm2. After 2 days, growth medium was replaced 
by osteogenic medium (including 100 nM dexamethasone, 
50 mM ascorbate-2-phosphate, and 10 mM glycerol 
phosphate). All chemicals were purchased from Sigma-
Aldrich, USA. Medium was replaced twice weekly. After 
18 days, cells were stained with Alizarin Red S to visu-
alize the calcify deposition.
In Vivo Implantation of Alginate Scaffolds
Experimental animals were handled in accordance 
with the European Animal Care Guidelines. Patch 
implantation was performed in adult female Sprague–
Dawley rats (200–250 g) by left thoracotomy via the 
fourth intercostal space under general anesthesia (iso-
flurane, 2.5%) and mechanical ventilation. Alginate 
scaffolds (n = 4 for each alginate type) were implanted 
onto the surface of the left ventricle after removal of 
the pericardium over two peripheral sutures using a 
7–0 prolene suture. Sham-operated animals were sub-
jected to the same surgical procedure without implan-
tation (n = 2).
Blood Analysis
Hematocrit measurement was performed on blood col-
lected by retro-orbital bleeding on anesthetized animals 
using heparinized tubes. Hematocrits were evaluated by 
standard microhematocrit method. Leukocyte differential 
count was performed on total blood collected on abdomi-
nal aorta (MICROS-60, ABX-Diagnostics, France).
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Echography
Left ventricular (LV) function was assessed in anes-
thetized animals with two-dimensional echocardiography 
with a General Electric Vivid 7® (GE Medical System, 
USA) equipped with a 13-MHz linear probe. For anesthe-
sia, rats were induced with isoflurane and received con-
tinuous inhaled anesthetic (2%) for the duration of the 
imaging session. The animals were placed in the supine 
or lateral position on a warming pad. Numeric images 
of the heart were obtained in both parasternal long-axis 
and short-axis views. Two-dimensional end-diastolic 
and end-systolic long-axis views of the LV were stan-
dardized as follows: inclusion of the apex, the posterior 
papillary muscle, the mitral valve, and the aortic root. 
Two-dimensional echocardiographic measurements were 
performed with the cine-loop feature to retrospectively 
catch true end-diastolic and end-systolic phases, defined 
as the phases in which the largest and the smallest LV cav-
ity sizes were obtained, respectively. End-diastolic and 
end-systolic areas (A) were obtained by hand tracings of 
the LV endocardial contours, according to the American 
Society of Echocardiography leading edge method. On 
these frames, end-diastolic and end-systolic lengths (L) 
of the LV were obtained by tracing a line connecting the 
more distal part of the apex and the center of a line con-
necting the mitral annular hinge points. End-diastolic 
and end-systolic volumes (LVEDVs and LVESVs, 
respectively) were then calculated by means of the sin-
gle-plane area-length method (volume = 8 × A2/3 × π × L). 
LV ejection fraction (LVEF, %) was calculated as 
[(LVEDV − LVESV)/LVEDV] × 100. All measurements 
were averaged on three consecutive cardiac cycles and 
analyzed by a single observer who was blinded to the 
treatment status of the animals.
Cyto- and Histological Examinations
Staining of MSCs extracted from microspheres was 
performed after alginate solubilization and cell removal. 
Cells were plated in six-well plate, fixed in 4% parafor-
maldehyde, and stained with Alizarin Red S, Alcian Blue, 
or Oil Red O coloration using standard procedures. For 
cell staining in embedded microspheres, paraffin sec-
tions of G-type and M-type alginate microspheres were 
rehydrated and incubated in the presence of biotinylated 
rat proliferating cell nuclear antigen (PCNA) according 
to the manufacturer’s recommendations. Sections were 
counterstained with hematoxylin. Sections of rat kidney 
regenerating after ischemia/reperfusion were used as 
positive control (29). For CD90 detection, paraffin sec-
tions of G-type and M-type alginate microspheres were 
rehydrated and incubated with anti-rat CD90 antibody 
(diluted 1:100, 60 min; Santa Cruz Biotechnology, CA). 
Antibody revelation was performed by using an Alexa 
Fluor 568 secondary antibody (1:500, 30 min; Invitrogen, 
CA). For nuclear detection, sections were incubated with 
to-pro-3 (1:1,000, 20 min; Invitrogen, CA). For histolog-
ical staining on explanted hearts, hearts were collected 
and fixed in Carnoy’s solution, and paraffin sections 
(6 µm) were rehydrated and stained with hematoxylin/
eosin coloration using standard methods. α-Smooth 
muscle actin (α-SMA)-staining implanted heart sections 
were rehydrated and incubated with mouse monoclonal 
anti-α-SMA (clone 1A4, Sigma, USA) for 1 h. Tissue was 
stained using the anti-mouse HRP-DAB and counter-
stained with hematoxylin.
Statistical Analysis
Results are expressed as mean ± SD. Statistical com-
parison of the data was performed using the t test for 
comparison between two groups or one-way ANOVA and 
post hoc Tukey’s test for comparison of more than two 
groups. A value of p < 0.05 was considered significant.
RESULTS
Characterization of Alginate Hydrogels 
Determination of Diadic Composition of Alginates. 
Gelification process of alginate is described by the “egg-
box” model where divalent cations are binded to regions 
enriched in G–G sequences to form intramolecular and/or 
intermolecular junctions. The ability of alginate to form 
a gel in presence of Ca2+ depends not only on its uronate 
composition but also on the repartition of mannuronic 
and guluronic residues along the polymeric chain (22). 
In this study, fraction of guluronic (FG) and mannuronic 
(FM) residues together with diadic composition (FGG, 
FGM, and FMM) of ultrapur alginates were determined by 
1H-RMN spectroscopy. G-type alginate presented signifi-
cantly more G residues and G–G sequences than M-type 
alginate (Table 1).
Mechanical Behavior of Alginate Hydrogels. Hydrogels 
synthesized with these two different alginates were then 
analyzed by measuring elastic modulus (G′) and loss 
modulus (G″) by oscillatory shear measurement in a 
rehometer. Whatever the frequency tested in their vis-
coelastic domain, both alginate types exhibited elastic 
moduli G′ higher than their loss moduli G″, confirming 
that both alginate types were under a hydrogel structured 
form at the calcium concentration tested for the experi-
ments (0.1 M). As a consequence of its higher G frac-
tion, G-type alginate calcium hydrogels presented higher 
moduli than M-type alginate hydrogels, revealing a 
higher structuration degree due to more calcium-binding 
sites (as can be seen in Table 1, for a frequency of 4 Hz). 
To complete calcium alginate hydrogels characterization, 
their mechanical properties were studied under compres-
sion strain. Young’s modulus presents the advantage not 
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to be dependent of the device geometry but only of the 
intrinsic mechanical properties of the materials. The 
mechanical behavior of the two alginates was assessed 
by three successive compressions, and Young’s modulus 
was determined at 50% of strain (Fig. 1). Alginate micro-
spheres presented a Young’s modulus near 38 and 25 kPa 
for G-type and M-type alginate, respectively. G-type 
alginate hydrogels showed a time-dependent mechanical 
resistance, which evidenced viscous or plastic behavior, 
while M-type alginate hydrogels maintained an elastic 
behavior over time.
Swelling Behavior of Alginate Hydrogels. Swelling 
behavior of alginate hydrogels is an essential parameter 
to describe the device stability in wet environment like 
during in vitro cultivation time or after animal implan-
tation. Consequently, alginate microspheres were 
synthetized and immersed for 28 days in iso-osmotic 
buffer, and their Sauter diameter d(3,2) was weekly 
assessed by laser diffractometry (Fig. 2). Microspheres 
sizes and distribution remained stable during the entire 
immersion test and could consequently be consid-
ered as adapted for in vitro and in vivo studies, as 
no swelling, a sign of hydrogel destabilization, could 
be observed.
Immobilized MSC Biological Properties
Viability of Entrapped MSCs. Bone marrow MSC 
via bility was assessed by confocal analysis. Encapsulated 
MSCs were cultured under proliferation conditions for 
28 days, and viability of cells in G-type and M-type alginate 
microspheres was weekly determined. Cell viability was 
maintained around 80% (Fig. 3A) for 21 days after encapsu-
lation; a slight decrease was observed from 28 days for both 
alginate types. Confocal z planes (Fig. 3B and C) of micro-
spheres at 21 days postencapsulation showed a homogenous 
distribution of viable cells in whole microspheres.
Cell density D was estimated at 151 ± 7.8 and 
167 ± 25.2 MSCs/mm2 for G-type and M-type alginate 
microspheres, respectively (mean ± SD; p > 0.05) and 
was found to remain stable along the study. Furthermore, 
MSC-encapsulated in G- and M-type microspheres 
did not exhibit any proliferation. Indeed, as observed 
in Figure 4A–D, G-type and M-type alginate micro-
sphere sections did not show PCNA immunostaining at 
day 28 postencapsulation. This observation, combined 
Table 1. Main Characteristics of Ultrapur Alginates Used in 
This Study
Parameters
Provona Up 
MVG
Provona Up 
MVM
FG
a 68% 45%
FGG
a 55% 28%
FGM
a 13% 17%
FMM
a 20% 38%
Elastic modulus (G′)b 31.1 ± 2.6 kPa 9.9 ± 2.7 kPa
Loss modulus (G″)b 4.2 ± 0.6 kPa 1.3 ± 0.5 kPa
A pparent viscosityc 
at 25°C, 1%
262 mPa.s 440 mPa.s
Protein contentc ≤0.1% ≤0.1%
Endotoxinsc <19 EU/g <25 EU/g
FG, G fraction; FGG, GG fraction; FGM, GM fraction; FMM, MM fraction.
a1H NMR measurement.
bRheological measurement at 4 Hz (mean ± standard deviation).
cData provided by Nova Matrix, FMC BioPolymer (Oslo, Norway). 
Figure 1. Mechanical properties of alginate hydrogels. 
Determination of Young’s modulus of G-type (black bars) and 
M-type (white bars) alginate hydrogels by stress measurement 
under three successive 50% compressive strains (1, 2, and 3). 
Error bars represent standard deviation; *p ≤ 0.05, **p ≤ 0.01 
based on ANOVA analysis. 
Figure 2. Swelling behavior of alginate hydrogels. Sauter diam-
eter d(3,2) of G-type (black bars) and M-type (white bars) algi-
nate microspheres immersed for 28 days in iso-osmotic buffer.
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with the absence of significant variation in cell density 
inside microspheres during culture time, suggests that 
encapsulated MSCs do not underlie proliferation. This 
may be related to an alginate/MSC contact inhibition due 
to the highly confined alginate microenvironment (26,45). 
These results suggest neither proliferation of MSCs in 
alginate microspheres nor MSCs decrease over time.
Functionality of Entrapped MSCs. Next we investi-
gated whether encapsulation may affect MSC pheno-
type. As a first approach, we demonstrated that, after 
28 days of encapsulation, 84% ± 3.76% and 86% ± 4.5% 
of the total cell population for G-type and M-type algi-
nates, respectively (mean ± SD; percentage determined 
by peroxidase revelation, p > 0.05), were positive for 
the MSC marker CD90. Then we investigated whether 
encapsulated MSCs undergo spontaneous differentiation 
toward classical mesodermal lineage. With this scope, 
we stained MSCs extracted from G-type or M-type algi-
nate after 28 days with Alizarin red S, Alcian Blue, and 
Red Oil O specific dyes for osteogenic, chondrogenic, 
and adipogenic lineage. As shown in Figure 5, in contrast 
to control MSCs in which specific lineage was chemically 
induced in vitro, MSCs eluted from microsphere were not 
stained by any of these dyes. This indicates that encapsu-
lation into G-type and M-type alginate did not induce the 
commitment of MSCs toward meso dermal lineage.
We have previously shown that paracrine factors, play-
ing a major role in the beneficial effect of cell therapy, 
were secreted by MSCs (36). As shown in Figure 6A, we 
found that expressions of cytokines normally produced 
by MSCs (VEGF, IGF-1, FGF2, HGF, EGF, and G-CSF) 
were increased for both alginate types as compared to 
nonencapsulated cells. In addition, the amount of intra-
cellular FGF2, quantified by Western blot, was not modi-
fied after MSC encapsulation (Fig. 6B).
Figure 3. Viability of entrapped MSCs in alginate hydrogels. Quantification of mesenchymal stem cell (MSC) viability (%) and algi-
nate cell density (cells/mm2) by confocal microscopy during 28 days of encapsulation in G-type (full line/black bars, respectively) or 
M-type (dot line/white bar, respectively) alginate microspheres (A). Confocal z planes of G-type (B) and M-type (C) alginate micro-
spheres after a live/dead staining after 21 days in culture. Five confocal z planes of G-type (D) and M-type (E) alginate microspheres 
after ethanol treatment showing a diffuse labeling of dead cells with some residual living cells. Scale bars: 200 µm.
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Figure 4. PCNA immunostaining of encapsulated MSCs. Proliferating cell nuclear antigen (PCNA)-immunostained G-type (A and 
B) and M-type (C and D) microspheres after 28 days postencapsulation. Sections of rat kidney regenerating after ischemia/reperfusion 
were used as positive control (E and F). Scale bars: 100 µm.
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In Vivo Alginate Scaffolds Cardiac Compatibility
Implantability of Alginate Scaffolds. Alginate scaf-
folds were implanted and fixed to the myocardium by 
two peripheral sutures. All were successfully attached. 
However, M-type alginate scaffolds appeared to be more 
difficult to manipulate during surgical intervention due to 
their friability and their poor mechanical properties. 
Cardiac Biocompatibility of Alginate Scaffolds. The 
effect of alginate scaffolds implantation on adult rat 
heart was studied. Hematocrits were weekly analyzed 
(Fig. 7A) during implantation time, and white blood 
cells (Fig. 7B) were numbered after 28 days postim-
plantation. No significant differences were observed 
for these parameters between control group, G-type 
and M-type alginate implanted groups, suggesting 
that rats did not present any sign of systemic infection 
or inflammation.
Cardiac function was weekly determined by echocar-
diography after implantation. Left ventricular end-dia-
stolic volumes (LVEDV; Fig. 8D), ejection fraction (EF; 
Fig. 8E), and heart rate (HR; Fig. 8F) showed no signifi-
cant change in comparison with nonimplanted rat and 
were stable for 1 month. 
Macroscopic and Microscopic Observations of 
Explants. Postmortem analyses after 28 days postim-
plantation revealed that no adherences were observed in 
the environment of implanted scaffolds. G-type alginate 
scaffolds were found still attached to the myocardium, 
conserving their initial morphology (Fig. 9A). On the 
contrary, M-type alginate scaffolds were found detached 
from suture, near the heart, in thoracic wall. They were no 
longer in a patch shape (Fig. 9B).
Eosin/hematoxylin staining of implanted heart revealed 
normal myocardium (Fig. 10A and B) with foreign body 
Figure 6. Paracrine activity of encapsulated MSCs. Relative quantification of transcript coding for growth factors in MSCs encap-
sulated in G-type (black bars) or M-type (white bars) alginate microspheres after 28 days of culture, normalized by glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and ribosomal protein L31 (RPL31), fold to control (A). Control is determined by cytokine 
expression in cultured MSCs. Quantification of intracellular fibroblast growth factor 2 (FGF2) in MSCs encapsulated in G-type (black 
bars) or M-type (white bars) alginates microspheres after 28 days of culture or nonencapsulated MSCs (gray bars) normalized by 
GAPDH (B).
FACING PAGE
Figure 5. CD90 detection and differentiation staining of entrapped MSCs. (A) Confocal microscopy observations of CD90 alone 
(a, b) or overlay (c, d) of CD90 and cell nuclei of entrapped MSCs in G-type (a, c) and M-type (b, d) at 28 days postencapsulation. 
(−) and (+) labeled arrows show CD90-negative MSC and CD90-positive MSC, respectively. (e and f ) Overlays of positive (rat MSCs) 
and negative controls (rat myocardium), respectively. Scale bars: 100 µm. (B) Specific coloration of osteogenic (Alizarin Red: a, 
b, and c), chondrogenic (Alcian Blue: d, e, and f), and adipogenic lineage (Red Oil: g, h, and i) of MSCs: optical microscopy of 28 days 
postencapsulated MSCs in G-type (a, d, and g) or M-type alginate hydrogels (b, e, and h). Positive controls: MSCs after induction of 
osteogenesis (c), chondrogenesis (f), and adipogenesis (i). Scale bars: 200 µm. 
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giant cells and macrophages at the alginate/myocardium 
interface. This histomorphological feature is compatible 
with a classical foreign body reaction probably related to 
alginate hydrogels. A weak fibrosis surrounding scaffolds 
was associated with the formation of neovascularization 
as indicated by arrows in Figure 10C. In the case of M-type 
alginate, the presence of fibers and cells infiltrating scaf-
folds was also observed (Fig. 10D). The granulation tis-
sue surrounding scaffolds formed a fibrous capsule. All 
together, these histomorphological features indicate that 
implantation of alginate microspheres induced a classical 
local inflammatory response, as previously reported by 
other groups (3,35,44).
DISCUSSION
Despite the success of alginate scaffolds and mesen-
chymal stem cells therapy in cardiac failure treatment, the 
impact of the physicochemical environment provided by 
alginate matrices on cell behavior has never been inves-
tigated in this application. The purpose of this work was 
double, to determine alginate composition influence on 
(1) encapsulated MSC viability, paracrine activity, and 
phenotype in vitro and (2) cardiac implantability and in 
vivo biocompatibility of patch shape scaffolds. 
In this study, two different alginates, both exhibiting a 
medium molecular weight, have been selected upon their 
M/G ratio: a low M/G ratio alginate, so-called G-type 
alginate, and a high M/G ratio alginate, so-called M-type 
alginate. NMR characterization showed that selected sam-
ples exhibit a G fraction of 68% and 45% and a G-blocks 
fraction of 55% and 28%, respectively. Shear measure-
ment and determination of swelling behavior revealed 
that calcium crosslinking of 1.2% G-type and M-type 
alginate permitted in both cases to obtain a structured 
and stable polymeric network corresponding to a hydro-
gel. Characterization of these calcium alginate hydrogels 
showed that the M/G ratio impacted not only the matrices 
mechanical strength but also their mechanical behavior: 
G-type hydrogels were more rigid and presented viscous 
and/or plastic behavior; on the contrary, M-type hydrogels 
were less rigid and exhibited an elastic behavior. These 
macroscopic observations can be explained by differ-
ences in chemical compositions and structure of the tested 
alginates. Effectively, their sol–gel transition involves 
an “egg-box” model (18) through the ionic interaction 
between divalent cations, in our case, Ca2+ ions, and adja-
cent guluronic residues of alginate chain. Therefore, when 
decreasing M/G ratio and increasing G-blocks content, a 
denser polymeric network can be obtained (22), leading 
to a more rigid scaffold, less able to swell after compres-
sion (40). These latter properties could explain the viscous 
and/or plastic mechanical behavior observed in the case 
of G-type hydrogels. Mechanical properties of G-type and 
M-type alginate hydrogels were statistically different, but 
both remained compatible with cardiac implantation, as 
their mechanical strengths match with myocardium tis-
sue Young’s modulus; their levels of elasticity seem to 
be in accordance with dynamical heart environment (66). 
Concerning MSCs, recent studies demonstrated that the 
mechanical properties of cell environment (provided by 
the biomaterial) can have a notifying impact on their 
behavior. Engler et al. (16) cultivated MSCs on polyacryl-
amide gels with varying Young’s moduli corresponding to 
the mechanical properties of various organs. They reported 
that MSCs committed the lineage specified by matrix elas-
ticity, predominantly to the lineage expected after specific 
cytokine induction. This influence of microenvironment 
chemical and physical properties was also observed on 
Figure 7. Evaluation of alginate hydrogels biocompatibility. Hematocrit levels of implanted rats 28 days after cardiac implantation 
(A) of G-type (full line), M-type (dot line) hydrogels and control group (dash line). White blood cell differential count 28 days after car-
diac implantation (C) of G-type (black bars) and M-type (white bars) alginate scaffolds implanted group and control group (gray bar).
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cells embedded in alginate hydrogels for diabetes therapy 
purpose. Alginate M/G ratio modulated entrapped murine 
insulinoma βTC3 cells functionality (10,23,50,51). Such 
phenomenon was also reported in the case of stem cells. It 
has been demonstrated that providing to neural stem cells 
an alginate environment whose mechanical properties 
are close to those of brain tissues can upregulate neural 
markers and modify their paracrine activities when vary-
ing alginate M/G ratio (5,47). Hence, the choice of alg-
inate composition when elaborating a scaffold, a fortiori 
in a cardiac application where scaffold mechanical behav-
ior appears as a critical parameter, is far from neutral. 
Surprisingly, it has never been studied till then. 
In this study, in vitro evaluation of G-type and M-type 
alginates confirmed that both hydrogels were good can-
didates for MSC encapsulation. MSC viability was main-
tained around 75% up to 28 days postencapsulation. 
Moreover, live/dead cells distribution inside microspheres 
suggested sufficient nutriments and oxygen diffusion in 
whole microparticles, a necessary prerequisite to main-
tain cell viability (37).
Functionality of encapsulated MSCs was evalu-
ated through the expression of cytokines responsible of 
MSCs’ beneficial effects. Bioactive factors secreted by 
MSCs possess angiogenic, antiapoptotic, and immu-
nomodulatory properties that may limit tissue damage 
Figure 8. Results of echographic measurement. Left: Echographic photography of implanted (A and B) and not implanted (C) hearts. 
G-type (A) and M-type (B) alginate scaffolds are indicated by arrows. For understanding facility scale bars corresponding to 5 mm 
have been added. Right: Left ventricular end-diastolic volumes (LVEDV, D), left ventricular ejection fraction (LVEF, E), and heart 
rate (HR, F) in beats per minute (BPM) of G-type (full line) and M-type (spot line) alginate scaffolds implanted rats and controls (dash 
line) 28 days after cardiac implantation. 
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extension at the injury site and promote blood supply 
(9,12,17,25). Among them, FGF-2, HGF, VEGF, G-CSF, 
EGF, and IGF-1 were clearly identified in literature 
(4,13,14,20,24,49,56), FGF-2 being the most abundant 
cytokine secreted by MSCs (36). The measurement of 
mRNA encoding for these factors and the quantification 
of intracellular FGF2 showed that MSC paracrine activity 
was maintained and even increased when encapsulated. 
Statistical analysis concerning the comparison of bio-
factor expression levels in encapsulated and nonencap-
sulated MSCs showed an overexpression of IGF-1 and 
HGF in the former case (p < 0.001). It has already been 
demonstrated that three-dimensional configuration can 
modify biofactor expression levels in encapsulated cells 
(11). Such mechanisms seem to be related to changes 
(i) in spatial and mechanical configuration mimicking in 
vivo environment and (ii) in cell morphology, movement, 
and density (16,28,51,60). 
Concerning cell phenotype, our results showed that 
most of the entrapped cells express the MSC marker 
CD90 and maintain the osteogenic, chondrogenic, and 
adipogenic lineage. These results confirm that most of 
the entrapped cells maintain the MSC phenotype. MSCs 
did not undergo transdifferentiation to classical osteo-
blast, chondroblast, and adipocyte lineages during culture 
period and expressed the MSC marker CD90, confirming 
that entrapped cells maintain an MSC phenotype.
Regarding MSC biological parameters investigated 
here, alginate M/G ratio had no direct impact on their 
behavior after 28 days of encapsulation. These results 
confirmed previous work from our laboratory, which 
demonstrated that encapsulation in alginate micropar-
ticles represents a promising approach for MSC engraft-
ment on solid organ (58). Our in vitro results suggest that 
entrapment in three-dimensional scaffolds elaborated 
with both types of alginates may represent an excellent 
alternative to direct intraparenchymal injection and could 
permit to take advantage of paracrine properties of MSCs 
in cell therapy. Nevertheless, this conclusion has to be 
modulated by our in vivo results. 
Implanted rats presented no sign of infection and 
a stable cardiac function, suggesting a good environ-
mental and mechanical compatibility of the devices 
on beating heart. Patch-shaped scaffolds from G-type 
and M-type alginate did not disturb cardiac function 
when implanted on the myocardium. Alginates biocom-
patibility in relation with their composition and more 
particularly with their M/G ratio has been a matter of 
controversy (27,43,44). Consensus is now established 
about the predominant influence of purity grade on alg-
inate immunogenicity (42,46). This point was confirmed 
by the observed maintained hematocrit level in both 
cases during the implantation period. In addition, both 
alginate scaffolds were well integrated in the myocar-
dial environment: microscopic observation of explants 
revealed a weak fibrosis associated with a vascularized 
tissue surrounding the devices. This latter observation is 
of importance, as oxygenation and nutrition of entrapped 
cells is a key parameter to obtain long-term viability of 
the graft, a point that actually limits the benefits of MSC 
cardiac therapy. Concerning cardiac implantability, two 
distinct in vivo behaviors were observed as a function 
of alginate M/G ratio. M-type alginate scaffolds have 
been more difficult to manipulate due to their lack of 
cohesion and lower rigidity when compared to G-type 
alginate scaffolds. These latter were easily manipulated 
by surgeon and fixed by suture to the myocardium. 
Twenty-eight days postimplantation, G-type scaffolds 
Figure 9. Macroscopic morphology of explanted alginate hydrogels. Photography of G-type (A) and M-type (B) alginate scaffolds 
explanted from the heart 28 days after implantation. Scale bars: 10 mm.
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were found on the myocardium, still fixed by the ini-
tial sutures, while M-type alginate scaffolds were found 
damaged and detached from sutures. Alginate degrad-
ability is generally reported to depend on molecular 
weight (6). In this study, G-type and M-type alginate 
viscosities were similar (262 and 440 mPa s, respec-
tively; Table 1), suggesting the same order of magnitude 
of their molecular weight. Hence, the observed M-type 
alginate patch destruction may be better related to hydro-
gel microstructure and resulting mechanical properties. 
Effectively, G-type alginates, containing a higher FGG 
fraction than M-type alginates, provide more binding 
sites for calcium ions, leading to more structured and 
rigid polymeric networks. Consequently, G-type alginate 
Figure 10. Twenty-eight days postimplantation microscopic analysis of explanted alginate hydrogels from the heart. Eosin/hematoxy-
lin staining of explanted G-type (A) and M-type (B and D) alginate scaffolds. α-SMA staining of explanted G-type alginate hydrogel 
(C); arrows indicate vascular formation in fibrotic tissue. Scale bars: 500 µm (A, B, and D) and 100 µm (C).
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scaffolds were able to support strain in a dynamic envi-
ronment, while less structured M-type alginate scaffolds 
could not.
CONCLUSION
This study presents a double interest: first, it vali-
dates the use of alginate three-dimensional scaffolds to 
take advantage of MSCs’ secretory abilities. Second, it 
points out the impact of alginates chemical composi-
tion and, consequently, mechanical behavior on scaffold 
performance in cardiac therapy field. Even if both alg-
inate types appear highly biocompatible, resulting scaf-
fold implantability and in situ mechanical resistance are 
to be considered. Alginate G-type hydrogels, exhibiting 
a higher structural and mechanical resistance, appeared 
better adapted to bear in vivo cardiac strain. 
This study permits expanded knowledge of the critical 
parameters to consider when considering an alginate MSC 
scaffold. However, many questions remain unsolved, par-
ticularly concerning the device optimal tridimensional 
geometry. Recent studies have highlighted the interest 
of a patch shape, but little is known concerning the opti-
mal porosity necessary to combine efficient cell loading, 
adequate mechanical properties, nutrients circulation, 
and vascular infiltration. Strategies to optimize alginates 
scaffold performance for MSC cardiac therapy are cur-
rently under investigation in our laboratory.
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